The Link between Mitochondrial Dysfunction and Sarcopenia: An Update Focusing on the Role of Pyruvate Dehydrogenase Kinase 4

Abstract

Sarcopenia, defined as a progressive loss of muscle mass and function, is typified by mitochondrial dysfunction and loss of mitochondrial resilience. Sarcopenia is associated not only with aging, but also with various metabolic diseases characterized by mitochondrial dyshomeostasis. Pyruvate dehydrogenase kinases (PDKs) are mitochondrial enzymes that inhibit the pyruvate dehydrogenase complex, which controls pyruvate entry into the tricarboxylic acid cycle and the subsequent adenosine triphosphate production required for normal cellular activities. PDK4 is upregulated in mitochondrial dysfunction-related metabolic diseases, especially pathologic muscle conditions associated with enhanced muscle proteolysis and aberrant myogenesis. Increases in PDK4 are associated with perturbation of mitochondria-associated membranes and mitochondrial quality control, which are emerging as a central mechanism in the pathogenesis of metabolic disease-associated muscle atrophy. Here, we review how mitochondrial dysfunction affects sarcopenia, focusing on the role of PDK4 in mitochondrial homeostasis. We discuss the molecular mechanisms underlying the effects of PDK4 on mitochondrial dysfunction in sarcopenia and show that targeting mitochondria could be a therapeutic target for treating sarcopenia.

Comparison between single-muscle evaluation and cross-sectional area muscle evaluation for predicting the prognosis in patients with oral squamous cell carcinoma: a retrospective cohort study

“…Additionally, myostatin and activins inhibit muscle growth through the Smad 2/3 signaling pathway ( 35 ). Insulin resistance and mitochondrial dysfunction further exacerbate muscle loss by impairing energy production and increasing oxidative stress ( 36 ). Hormonal fluctuations, especially in testosterone and growth hormone, also contribute to sarcopenia’s development ( 37 ).…”

Metabolic clues to aging: exploring the role of circulating metabolites in frailty, sarcopenia and vascular aging related traits and diseases

“…Moreover, pyruvate can directly produce NAD + ( Zhou, 2021 ). In addition, pyruvate dehydrogenase kinases (PDKs), which regulate pyruvate’s entry into the tricarboxylic acid cycle, are implicated in muscle formation and atrophy, making them potential therapeutic targets for sarcopenia ( Kim et al, 2023 ). An experimental study also highlighted the sarcoprotective role of pyruvate dehydrogenase B (PDHB) ( Jiang et al, 2023 ).…”

Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases

“…119 In ALS, instability of the neuromuscular junction induces elevated PDK4 expression, which prevents the entry of pyruvate into the TCA cycle. 120,121 Energy deficiency leads to more fatty acids entering the glycolytic muscle, which further induces the transcription of the nuclear hormone receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) to stimulate forkhead box transcription factor O1 (FOXO1), and high levels of FOXO1, as well as ATP and NADH generated by β-oxidation, can activate the expression of PDK4, which further inhibits glucose oxidation and creates a vicious cycle, with increased oxidative stress leading to neuronal death. 49,122,123…”